65,437 trials
Atrial Fibrillation (AF) · Magnesium Sulfate · Post Cardiac Surgery Patients
Primary: Number of Participants With New Episodes of Atrial Fibrillation — 12; 27 participants
Hearing Loss
Primary: Speech Clarity — 77.2; 76.6; 63.6 units on a scale — p=<0.05
Intermediate Stage of Hepatocellular Carcinoma · Hepatocellular Carcinoma
Primary: Objective Response Rate (ORR) — 11 Participants
HIV Infections
Primary: Percentage of Participants With Sustained Virologic Suppression — 67.7; 75.5; 0; 0.3 Percentage of participants
Bipolar I Disorder
Primary: Number of Participants Who Experience One or More Adverse Events (AEs) — 9; 4; 1; 4 Participants
Smoking Cessation
Primary: Feasibility as Assessed by Number of Participants Recruited for the Study — 100 Participants
Enteric Fever
Primary: Number of Participants With Treatment Emergent Adverse Events — 4; 9; 8; 9 Participants
Chronic Actinic Dermatitis
Primary: 50% Reduction in the Eczema Area and Severity Index Score (EASI-50) — 12; 9 Participants
H.Pylori Infection
Primary: Eradication Rate of H.Pylori Infection — 323; 304 Participants
Human Immunodeficiency Virus
Primary: Evidence of Toxicity. Toxicity Was Measured as Any Adverse Event; Nausea, Vomiting, Diarrhea. Elevated Liver Function Tests. — 4; 4 adverse events
Body Fat Disorder
Primary: Number of Participants With Device and/or Procedure Related Adverse Events (AEs) and Device-related Serious Adverse Events (SADEs) — 0; 0 participants
Strength · Range of Motion · Pain-Knee
Primary: Range of Motion — 74.0625; 80.3125 Degrees
HIV Pre-Exposure Prophylaxis
Primary: Proportion of Participants Reporting PrEP Initiation by 3 Months — 0.33; 0.10 proportion of participants
Alcohol Drinking
Primary: Perceived Message Effectiveness — 2.66; 2.54; 2.52; 2.50 score on a scale — p=<0.001
Alcohol Use Disorder
Primary: Number of Serious Adverse Events (Safety and Tolerability) — 1; 1 Adverse Events